Single Monoclonal Antibodies Should Not Be Used for COVID-19 Therapy: A Call for Antiviral Stewardship.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39115342.
- Also identified by DOI 10.1093/cid/ciae408.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The COVID-19 pandemic witnessed the greatest deployment of monoclonal antibody (mAb) therapies for an infectious disease, but all were defeated by SARS-CoV-2 evolution. As new mAbs are developed, the infectious disease community needs stewardship practices to reduce emergence of resistance.
Medical subject headings
- Antibodies, Monoclonal
- SARS-CoV-2
- COVID-19
- Antiviral Agents
- COVID-19 Drug Treatment